Celcuity spent $12.1 million less on clinical trials during the six months ended June 30, largely because VIKTORIA-1 Phase 3 costs fell. It also spent $5.0 million less on license milestones. Those specific development costs fell, at least for now.
The cash balance got much bigger too. Cash rose to $182.0 million from $46.4 million, but that was chiefly a financing event: financing activities supplied $422.9 million. Operating cash flow went the other way, falling to negative $110.5 million from negative $72.1 million.
That is the filing's central trade-off. Celcuity reduced trial spending and research and development costs fell 14.7%, but the company still recorded a $66.1 million operating loss, versus $44.0 million in the comparable six months. Net loss widened to $78.9 million from $45.3 million.
Celcuity described the clinical-cost reduction this way:
"The decrease was primarily due to a $12.1 million decrease in clinical trial costs, which was primarily driven by decreased costs for the VIKTORIA-1 Phase 3 clinical trial, and a $5.0 million decrease in license milestone costs."
Celcuity 10-Q, Aug. 13, 2026
The savings are specific, not a broad claim that the business now costs less to run. At the same time, the filing attributes part of an increase to commercialization and infrastructure.
Management said selling, general and administrative expenses are headed higher as REVTORPYK moves toward launch:
"We anticipate that our selling, general and administrative expenses will continue to increase in future periods, reflecting both increased costs in connection with the commercialization of REVTORPYK, an expanding infrastructure, and increased professional fees associated with public company regulatory developments and requirements, and other compliance matters."
Celcuity 10-Q, Aug. 13, 2026
The latest six months already contain that shift. Celcuity said $14.8 million of the remaining increase came from pre-commercial launch activities, including consulting, professional fees, and expanding infrastructure, while other administrative expenses added $3.3 million.
The filing also shows a larger ownership base. Diluted shares rose to 54.8 million from 43.7 million, a 25.5% increase, while stock compensation, a non-cash expense, increased to $6.9 million from $2.7 million. More cash is available, but more shares now represent the company.
The commercial plan is tied to a real licensing relationship rather than an unnamed future asset. Celcuity wrote:
"Upon the execution of the Pfizer license agreement in April 2021, we acquired exclusive world-wide licensing rights to develop and commercialize gedatolisib."
Celcuity 10-Q, Aug. 13, 2026
Celcuity's next quarterly report will put the launch spending alongside operating cash flow again, which should make clearer whether the lower VIKTORIA-1 costs are a temporary phase change or part of a lasting spending pattern. For now, the six-month math is plain: less trial spend, more launch spend, and more shares.
Celcuity's six-month trade-off: less trial spend, more launch spend, and more shares.